Federated Hermes’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-23,061
| Closed | -$3.14M | – | 2416 |
|
|
2020
Q3 | $3.14M | Sell |
23,061
-7,234
| -24% | -$769K | 0.01% | 851 |
|
|
2020
Q2 | $2.93M | Sell |
30,295
-20,357
| -40% | -$1.7M | 0.01% | 861 |
|
|
2020
Q1 | $2.38M | Buy |
50,652
+50,376
| +18,252% | +$3.23M | 0.01% | 838 |
|
|
2019
Q4 | $20K | Sell |
276
-9,887
| -97% | -$600K | ﹤0.01% | 1835 |
|
|
2019
Q3 | $530K | Buy |
+10,163
| New | +$540K | ﹤0.01% | 1440 |
|
|
2019
Q2 | – | Sell |
-22,720
| Closed | -$1.18M | – | 2263 |
|
|
2019
Q1 | $1.18M | Sell |
22,720
-364,328
| -94% | -$16.8M | ﹤0.01% | 1250 |
|
|
2018
Q4 | $18.9M | Buy |
387,048
+27,773
| +8% | +$1.53M | 0.05% | 321 |
|
|
2018
Q3 | $23.4M | Hold |
359,275
| – | – | 0.05% | 316 |
|
|
2018
Q2 | $17.8M | Buy |
359,275
+149,721
| +71% | +$7.25M | 0.05% | 285 |
|
|
2018
Q1 | $10.2M | Sell |
209,554
-106
| -0.1% | -$5.51K | 0.03% | 418 |
|
|
2017
Q4 | $8.83M | Buy |
209,660
+209,649
| +1,905,900% | +$8.08M | 0.02% | 458 |
|
|
2017
Q3 | $1K | Buy |
+11
| New | +$351 | ﹤0.01% | 2114 |
|
Federated Hermes's MYOK Position: Q4 2020 in Review
Federated Hermes sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 23,061 shares — an estimated $3.14M sold.
Federated Hermes first reported a position in MYOK in Q3 2017 and held it in 12 quarters. The position peaked at $23.4M in Q3 2018. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- Federated Hermes reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- Federated Hermes sold 23,061 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $3.14M.
- Federated Hermes first reported a position in MyoKardia, Inc. Common Stock in Q3 2017 and held it in 12 quarters.
- Federated Hermes's MyoKardia, Inc. Common Stock position peaked at $23.4M in Q3 2018.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on Federated Hermes's 13F filing for Q4 2020, filed 12 Feb 2021.